Galena Biopharma (GALE) Misses Q1 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Noble Financial Keeps Galena (GALE) at 'Buy'; Interim NeuVax Phase 3 Data Now in Focus
May 11, 2016 3:12 PM EDTNoble Financial maintains its Buy rating and $3.50 price target on Galena Biopharma, Inc. (Nasdaq: GALE) following Q1 results and update issued Tuesday night.
Analyst Kumaraguru Raja commented, 70 events reached in March and interim safety and futility analysis announcement expected at end... More
Maxim Group Bullish on Galena Biopharma (GALE) Into Interim Analysis of PRESENT Study
May 11, 2016 7:25 AM EDTMaxim Group analyst Jason Kolbert reiterated a Buy rating and $4 price target on Galena Biopharma (NASDAQ: GALE), saying it 'offers a PRESENT as the data chain chugs along'. Next up is interim analysis.
Kolbert highlighted:
Galena is now cash rich. Management announced a debt financing (May 10, 2016) with the issuance of $25.5M in debentures (30-month term), bringing in $23.4M in net... More